Divi's Laboratories report 9% rise in net profit in Q3
Updating on US-FDA inspection, Divi's Lab said, "It has filed its comprehensive response to the observations of the FDA regulator within the stipulated time. Now it awaits for review from the US pharma regulator.
During the nine month period, Divi's Lab has capitalized assets of Rs 180 crore for creation of additional capacities at the existing manufacturing sites. Photo: Official Website